首页> 美国卫生研究院文献>Drug Design Development and Therapy >No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone a Peroxisome Proliferator-Activated Receptor-γ Agonist in Healthy Subjects

【2h】

No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone a Peroxisome Proliferator-Activated Receptor-γ Agonist in Healthy Subjects

机译：在健康受试者中钠葡萄糖共转运蛋白-2抑制剂Empagliflozin和Lobeglitazone之间没有相关的药代动力学药物 - 药物 - 药物 - 药物 - 药物 - 活血分子激活的受体-γ激动剂

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Drug Design Development and Therapy
作者
Yu Kyong Kim; Jun Gi Hwang; Min Kyu Park;
展开▼
作者单位

展开▼
年(卷),期 2021(-1),-1
年度 2021
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类药学;药物化学;
关键词
clinical trial; antidiabetic drug; pharmacokinetic interaction; thiazolidinedione; type 2 diabetes;

机译：临床试验;抗糖尿病药物;药代动力学相互作用;噻唑烷二酮;2型糖尿病;

相似文献

外文文献
中文文献
专利

1. Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-γ agonist, after a single oral administration in healthy female subjects [J] . ParkM.K., KimT.-E., KimJ., Clinical drug investigation . 2014,第7期

机译：在健康女性受试者中单次口服给药后，新型过氧化物酶体增殖物激活的受体-γ激动剂洛贝格列酮的耐受性和药代动力学
2. Pharmacokinetic Interaction Between Amlodipine and Lobeglitazone, a Novel Peroxisome Proliferator-activated Receptor-gamma Agonist, in Healthy Subjects [J] . Kim Choon O. K., Oh Eun Sil, Kim Chin, Clinical therapeutics . 2015,第9期

机译：氨氯地平和洛贝格列酮（一种新型的过氧化物酶体增殖物激活的受体-γ激动剂）在健康受试者中的药代动力学相互作用。
3. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-gamma agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects. [J] . Kim JW, Kim JR, Yi S, Clinical therapeutics . 2011,第11期

机译：Lobeglitazone（CKD-501）（一种过氧化物酶体增殖物激活的受体-γ激动剂）的耐受性和药代动力学：单剂量和多剂量，双盲，随机对照研究，针对健康的韩国男性受试者。
4. Using Natural Language Processing to Identify Pharmacokinetic Drug- Drug Interactions Described in Drug Package Inserts [C] . Richard Boyce, Gregory Gardner, Henk Harkema 11th Workshop on biomedical natural language processing 2012 . 2012

机译：使用自然语言处理来识别药物包装插页中描述的药代动力学药物-药物相互作用
5. Peroxisome Proliferator-activated Receptor-γ (PPARγ) Agonists: Potential Novel Treatment for HIV-1 Associated Brain Inflammation [D] . Omeragic, Amila . 2020

机译：过氧化物体增殖物激活受体-γ（PPARγ）激动剂：对HIV-1相关脑炎症的潜在新待遇
6. Lack of the effect of lobeglitazone a peroxisome proliferator-activated receptor-γ agonist on the pharmacokinetics and pharmacodynamics of warfarin [O] . Jin Ah Jung, Soo-Yun Lee, Tae-Eun Kim, 2015

机译：过氧化物酶体增殖物激活受体-γ激动剂洛贝格列酮对华法林的药代动力学和药效学缺乏影响
7. Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study [O] . György Jermendy, Zoltán Kiss, György Rokszin, 2018

机译：持续治疗新型抗糖尿病药物（二肽基肽酶-4抑制剂，钠葡萄糖共转运蛋白-2抑制剂和胰高血糖素样肽-1受体激动剂），其患有2型糖尿病的人：全国范围内的队列研究

No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone a Peroxisome Proliferator-Activated Receptor-γ Agonist in Healthy Subjects

著录项

相似文献

相关主题

期刊订阅